Form 4: Denali Therapeutics Director Marc Tessier-Lavigne Reports Stock and Option Awards

Director Marc Tessier-Lavigne reports acquisition of stock and option awards in Denali Therapeutics.

Summary

• On May 31, 2024, Marc Tessier-Lavigne, a director of Denali Therapeutics Inc., reported the acquisition of 5,967 shares of common stock represented by Restricted Stock Units (RSUs) and a contingent right to receive one share of common stock of the Issuer at $0.
• He also acquired 17,901 stock options with an exercise price of $18.56.
• These RSUs and options vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following these transactions, Tessier-Lavigne directly owns 1,880,539 shares of Denali Therapeutics common stock, including unvested RSUs.
• He also indirectly owns shares through several irrevocable trusts for which he serves as trustee: The Tessier-Lavigne/Hynes Irrevocable Trust 1 (78,848 shares), Trust 2 (79,173 shares), and Trust 3 (78,848 shares).
• He also directly owns 17,901 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options by a director is generally viewed as a positive sign, but it's not a strong indicator of future performance.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and options is contingent upon the earlier of the one-year anniversary of the grant date or the day preceding the next annual meeting of stockholders.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. This Form 4 filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in the biotechnology industry.
• Companies like Biogen, Amgen, and Regeneron use similar equity-based compensation plans to align the interests of management with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry standards for companies of similar size and stage of development.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates